Editor’s Choice: Balance Awareness Week and Study Updates

Happy Friday! Sept. 13-19 is Balance Awareness Week. It's intended to bring attention to balance-related vestibular disorders such as Meniere’s disease and vestibular migraine. Looking for ways to help out?…

Continue Reading Editor’s Choice: Balance Awareness Week and Study Updates
AChR Antibodies and C5a Protein are MG Severity Biomarkers
kalhh / Pixabay

AChR Antibodies and C5a Protein are MG Severity Biomarkers

To determine disease progression and severity, researchers often use biomarkers, a measurable substance that indicates disease state. According to Myasthenia Gravis News, a new study shows that acetylcholine receptor (AChR)…

Continue Reading AChR Antibodies and C5a Protein are MG Severity Biomarkers
Eculizumab Shows Long Term Benefits for Refractory Myasthenia Gravis
source: pixabay.com

Eculizumab Shows Long Term Benefits for Refractory Myasthenia Gravis

By Lauren Taylor from In The Cloud Copy Myasthenia gravis is an autoimmune condition characterized by muscle weakness and fatigue of muscles that are under the patient’s voluntary control. This…

Continue Reading Eculizumab Shows Long Term Benefits for Refractory Myasthenia Gravis
ICYMI: Stress and Depression Positively Correlated with Myasthenia Gravis Relapse
source: pixabay.com

ICYMI: Stress and Depression Positively Correlated with Myasthenia Gravis Relapse

by Lauren Taylor from In The Cloud Copy Myasthenia gravis is a neuromuscular disorder characterized by rapid fatigue and weakness of any muscles that are under the voluntary control of…

Continue Reading ICYMI: Stress and Depression Positively Correlated with Myasthenia Gravis Relapse
Study Suggests Rituximab Effective for Refractory Juvenile Myasthenia Gravis
source: pixabay.com

Study Suggests Rituximab Effective for Refractory Juvenile Myasthenia Gravis

  In many cases, autoimmune disorders like myasthenia gravis are treatable. However, there are some cases of refractory (treatment resistant) myasthenia gravis that presents an unmet patient need. However, researchers…

Continue Reading Study Suggests Rituximab Effective for Refractory Juvenile Myasthenia Gravis
Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions
source: pixabay.com

Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions

An investigative therapy for hemolytic disease of the fetus and newborn (HDFN) has just received the FDA's Rare Pediatric Disease and Orphan Drug Designations. This therapy is called nipocalimab and…

Continue Reading Nipocalimab is Making Progress in Four Clinical Trials for Autoimmune and Alloimmune Conditions
Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
source: pixabay.com

Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study

According to a story from Myasthenia Gravis News, a recent case report describes a unique case of a 60 year old male multiple myeloma patient. After receiving treatment for the…

Continue Reading Patient Treated for Multiple Myeloma Develops Myasthenia Gravis: Case Study
June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness
source: pixabay.com

June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness

June is recognized as Myasthenia Gravis Awareness Month. Primarily organized by the Myasthenia Gravis Foundation of America (MGFA), this event is focused on spreading awareness as well as boosting efforts…

Continue Reading June is Myasthenia Gravis Awareness Month: Spreading Rare Disease Awareness
ICYMI: This Experimental Treatment Could Help Myasthenia Gravis Patients
source: pixabay.com

ICYMI: This Experimental Treatment Could Help Myasthenia Gravis Patients

According to a story from UNC Health Care, the Belgian drug company Argenx recently announced that its investigational treatment efgartigimod has performed well in a phase 3 clinical trial. The…

Continue Reading ICYMI: This Experimental Treatment Could Help Myasthenia Gravis Patients
Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
source: pixabay.com

Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis

  According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…

Continue Reading Positive Phase III Trial Results Show Efgartigimod as Effective for Myasthenia Gravis
New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients
source: pixabay.com

New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients

  New information, speculation, statistics, and predictions about COVID-19 are hitting the internet every day. Yet neurologists are attempting to answer their patients’ questions without having sufficient data that would…

Continue Reading New International Working Group Answers COVID-19 Questions from Myasthenia Gravis Patients
Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients
source: pixabay.com

Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients

According to a story from NeurologyLive, patients being treated for autoimmune diseases such as multiple sclerosis (MS) or myasthenia gravis could be at heightened risk of infection with coronavirus because…

Continue Reading Here’s How Coronavirus/COVID-19 Could Impact Multiple Sclerosis Patients
Close Menu